Search / Trial NCT06616675

Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1

Launched by HOSPITAL UNIVERSITÁRIO PROFESSOR EDGARD SANTOS · Sep 25, 2024

Trial Information

Current as of October 09, 2024

Completed

Keywords

Electrical Stimulation Overactive Bladder Hltv 1 Darifenacin

Description

Subjects presenting OAB according to ICS, associated with the HTLV-1 infection were invited by the investigators to participate in the study according inclusion criteria . Participants who accepted were randomly allocated to two groups (G1 and G2) by the free randomization website. Group 1 was treated with Darifenacin, and group 2 with the PTENS protocol. Drug Treatment Protocol: The anticholinergic Fenazic (Adium) was used in a single dose of 15mg/day for 2 months. PTENS Protocol: The treatment consisted of PTENS with the Neurodyn Portable TENS FES(21) neuromuscular stimulation device ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * HTLV-1 infection
  • * Overactive bladder symptom
  • * 18 years of age or older
  • Exclusion Criteria:
  • * HTLV-1 infected subjects with HAM
  • * Stroke
  • * Parkinson
  • * HIV infection
  • * Prostatic hyperplasia
  • * Pacemaker use
  • * Genitourinary tract infection
  • * Glaucoma

About Hospital Universitário Professor Edgard Santos

Hospital Universitário Professor Edgard Santos (HUPE) is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and patient care. Affiliated with the Federal University of Bahia, HUPE integrates education, research, and clinical practice, fostering a multidisciplinary approach to health sciences. The hospital conducts a wide range of clinical trials aimed at improving treatment outcomes and contributing to the scientific community. With a commitment to excellence and patient-centered care, HUPE plays a pivotal role in translating research findings into practical applications that enhance health and well-being in the region and beyond.

Locations

Salvador, Ba, Brazil

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0